Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-02-06 @ 12:26 AM
Study NCT ID:
NCT03801434
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2019-01-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Sponsor:
William Shomali
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | BCR-JAK2 Fusion Protein Expression | View |
| None | Blasts 20 Percent or Less of Peripheral Blood White Cells | View |
| None | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | View |
| None | Blasts More Than 5 Percent of Peripheral Blood White Cells | View |
| None | Blasts Under 20 Percent of Bone Marrow Nucleated Cells | View |
| None | Chronic Eosinophilic Leukemia, Not Otherwise Specified | View |
| None | Eosinophilia | View |
| None | Hepatomegaly | View |
| None | Hypereosinophilic Syndrome | View |
| None | JAK2 Gene Mutation | View |
| None | Splenomegaly | View |
| None | TEL-JAK2 Fusion Protein Expression | View |
Keywords: